Trial Condition(s):
Carcinoma, Renal Cell
Nexavar dosing in renal cancer patients in "real-life" setting (NEXST)
Bayer Identifier:
16268
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.
Inclusion Criteria
- Age >/= 18 years - Diagnosis of renal cell carcinoma - Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or disqualified from therapy with IFN/IL-2 - Patients in whom the oncologist has decide to start therapy with sorafenib.
Exclusion Criteria
-Synonymous with contraindications to Nexavar.
Trial Summary
Enrollment Goal
205
Trial Dates
Phase
N/A
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Poland | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Nexavar dose evaluation study in patients with advanced renal cell carcinoma
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Percentage of patients in whom the actual dose of sorafenib equaled the planned doseTimeframe: 12 months
Secondary Outcome
- Overall tolerability of treatment as measured by rate of adverse eventsTimeframe: 12 months
Additional Information
Copyright © Bayer
Powered by
